Novo Nordisk Gains as Ozempic Found To Lower Dementia Rates

Key TakeawaysAmerican depositary receipts (ADRs) of Novo Nordisk rose in intraday trading Friday after an Oxford study showed the Danish company’s Ozempic diabetes drug was linked to lower rates of dementia.The drug also has been linked to a reduction in a range of mental problems, according to an article in The Lancet’s eClinicalMedicine journal.The study is the latest to show that semaglutide, the active ingredient in both Novo Nordisk’s Ozempic and its obesity medicine Wegovy, can treat more than diabete ...